Free Trial
NASDAQ:JANX

Janux Therapeutics (JANX) Stock Price, News & Analysis

Janux Therapeutics logo
$24.20 +1.51 (+6.65%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$24.54 +0.34 (+1.42%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Janux Therapeutics Stock (NASDAQ:JANX)

Advanced

Key Stats

Today's Range
$22.60
$24.24
50-Day Range
$21.77
$25.53
52-Week Range
$21.73
$71.71
Volume
1.05 million shs
Average Volume
783,664 shs
Market Capitalization
$1.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.31
Consensus Rating
Moderate Buy

Company Overview

Janux Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

JANX MarketRank™: 

Janux Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 728th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Janux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 13 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Janux Therapeutics has a consensus price target of $78.31, representing about 223.6% upside from its current price of $24.20.

  • Amount of Analyst Coverage

    Janux Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Janux Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Janux Therapeutics is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Janux Therapeutics is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Janux Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Janux Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.35% of the float of Janux Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Janux Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Janux Therapeutics has recently increased by 3.11%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Janux Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Janux Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.35% of the float of Janux Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Janux Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Janux Therapeutics has recently increased by 3.11%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Janux Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    27 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 575% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Janux Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Janux Therapeutics is held by insiders.

  • Percentage Held by Institutions

    75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Janux Therapeutics' insider trading history.
Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JANX Stock News Headlines

Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $78.31
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
Janux Therapeutics resumed with a Buy at Stifel
See More Headlines

JANX Stock Analysis - Frequently Asked Questions

Janux Therapeutics' stock was trading at $53.54 at the beginning of the year. Since then, JANX shares have decreased by 54.8% and is now trading at $24.20.

Janux Therapeutics, Inc. (NASDAQ:JANX) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.07.

Janux Therapeutics (JANX) raised $152 million in an IPO on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/07/2025
Today
10/08/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JANX
CIK
1817713
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$200.00
Low Price Target
$41.00
Potential Upside/Downside
+223.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.99 million
Net Margins
N/A
Pretax Margin
-24,064.01%
Return on Equity
-11.48%
Return on Assets
-11.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
47.03
Quick Ratio
47.03

Sales & Book Value

Annual Sales
$439 thousand
Price / Sales
3,312.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$19.49 per share
Price / Book
1.24

Miscellaneous

Outstanding Shares
60,094,000
Free Float
55,226,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
2.82
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:JANX) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners